Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Alnylam pharmaceuticals, inc. source : Www.biospace.com save search
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Published: 2024-03-20 (Crawled : 13:00) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.11%
H: 0.43%
C: -0.01%
cardiology results study
Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors
Published: 2024-03-19 (Crawled : 15:00) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.33%
H: 1.88%
C: 0.84%
therapeutics
Zenas BioPharma Appoints Patricia Allen to its Board of Directors
Published: 2024-03-06 (Crawled : 16:00) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.31%
H: 0.06%
C: -0.33%
biopharma
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published: 2024-03-05 (Crawled : 16:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
positive blood care topline results study
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule
Published: 2024-03-05 (Crawled : 15:30) - biospace.com/
VIR | $8.55 -4.68% -4.91% 770K
|
Health Technology
|
| O: -0.09%
H: 2.06%
C: -2.68%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.73%
H: 1.52%
C: 0.5%
hepatitis trial
Alnylam to Webcast Presentations at Upcoming March Investor Conferences - February 27, 2024
Published: 2024-02-27 (Crawled : 14:00) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.84%
H: 0.82%
C: -0.63%
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-02-22 (Crawled : 00:00) - biospace.com/
XNCR | $20.09 -1.9% -1.94% 390K
|
Health Technology
|
| O: -0.87%
H: 2.89%
C: 2.14%
VIR | $8.55 -4.68% -4.91% 770K
|
Health Technology
|
| O: -0.69%
H: 2.99%
C: 2.59%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.17%
H: 6.18%
C: 5.4%
year update financial results
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published: 2024-02-15 (Crawled : 14:30) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 1.16%
H: 1.48%
C: 0.89%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.86%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -8.62%
H: 2.18%
C: -1.71%
year pharmaceuticals financial results
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-01-29 (Crawled : 14:30) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.27%
H: 1.32%
C: 1.02%
conference year financial results
Opinion: Brain Health Matters; We Must Not Lose Momentum
Published: 2024-01-08 (Crawled : 07:00) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.05%
H: 4.12%
C: 3.98%
health momentum
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
Published: 2024-01-02 (Crawled : 13:30) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.8%
H: 3.23%
C: 2.66%
conference presentation
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Published: 2023-12-13 (Crawled : 14:30) - biospace.com/
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -0.06%
H: 2.36%
C: 2.36%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: -0.27%
H: 2.28%
C: 2.16%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: -0.14%
H: 4.22%
C: 3.97%
day innovation pipeline platform
Alnylam to Webcast Virtual R&D Day - December 6, 2023
Published: 2023-12-06 (Crawled : 14:30) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.37%
H: 3.09%
C: 2.35%
day
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
Published: 2023-11-30 (Crawled : 15:30) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.93%
H: 2.49%
C: 1.64%
work
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
VIR | $8.55 -4.68% -4.91% 770K
|
Health Technology
|
| O: 1.02%
H: 4.5%
C: 3.38%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.04%
H: 1.92%
C: 1.89%
meeting hepatitis liver ongoing trials today
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 15:00) - biospace.com/
VIR | $8.55 -4.68% -4.91% 770K
|
Health Technology
|
| O: 0.98%
H: 7.06%
C: 6.93%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 0.49%
H: 0.74%
C: -2.08%
meeting hepatitis liver ongoing trials
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023
Published: 2023-11-07 (Crawled : 15:00) - biospace.com/
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
SMMT | $3.65 -0.41% -0.41% 890K
|
Health Technology
|
| O: -0.46%
H: 6.68%
C: -11.75%
PLSE | $7.83 8.45% 7.79% 330K
|
Health Technology
|
| O: 0.39%
H: 6.43%
C: 1.92%
BIIB | $196.76 -0.72% -0.72% 1.2M
|
Health Technology
|
| O: -0.82%
H: 0.73%
C: -0.4%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 1.06%
H: 2.42%
C: 0.76%
therapeutics financial results
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - November 7, 2023
Published: 2023-11-07 (Crawled : 14:00) - biospace.com/
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 1.06%
H: 2.42%
C: 0.76%
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-02 (Crawled : 00:00) - biospace.com/
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: -0.89%
H: 0.0%
C: 0.0%
XNCR | $20.09 -1.9% -1.94% 390K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
VIR | $8.55 -4.68% -4.91% 770K
|
Health Technology
|
| O: 1.03%
H: 4.07%
C: 4.07%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
update financial results
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Published: 2023-11-02 (Crawled : 13:00) - biospace.com/
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 3.0%
H: 0.0%
C: 0.0%
ALNY | $147.775 -0.49% -0.49% 490K
|
Health Technology
|
| O: 3.4%
H: 0.57%
C: -0.5%
pharmaceuticals financial results
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.